These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9309088)

  • 1. Systemic treatment for stage I and stage II breast cancer.
    Hudis CA; Borgen P
    Surg Oncol Clin N Am; 1997 Oct; 6(4):683-98. PubMed ID: 9309088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant drug therapy for operable breast cancer.
    Hudis CA; Norton L
    Semin Oncol; 1996 Aug; 23(4):475-93. PubMed ID: 8757274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breast carcinoma--adjuvant chemo- and hormone therapy].
    Fey MF
    Ther Umsch; 1998 Jul; 55(7):413-4. PubMed ID: 9702106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH; Cosler LE; Kuderer NM; Hornberger J
    Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advance in adjuvant therapy for breast cancer].
    Shimizu C; Watanabe T
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma.
    Jackson JS; Olivotto IA; Wai M D E; Grau C; Mates D; Ragaz J
    Cancer; 2000 Apr; 88(8):1852-62. PubMed ID: 10760762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
    Dixon JM
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
    Karlsson YA; Malmström PO; Hatschek T; Fornander TG; Söderberg M; Bengtsson NO; Jansson TE; Sjöberg SM; Bergh JC
    Cancer; 1998 Sep; 83(5):936-47. PubMed ID: 9731898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
    Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.